Subscribe to Newsletter

Other

Business & Profession Other

Stats on stats

| Mark Hillen

An advanced level of statistical knowledge is necessary to critically appraise most ophthalmology literature.

Subspecialties Other

Glaucoma awareness from a global perspective

| Richard Gallagher

To mark World Glaucoma Week, here are some of the many creative approaches being taken to communicate awareness of the disease around the world.

Business & Profession Professional Development

How to Improve Visual Acuity Testing

| Florian Kretz

The Salzburg Reading Desk is one promising approach to standardizing visual assessments for multifocal intraocular lenses.

Business & Profession Professional Development

Why Snellen Must Die

| Mark Blecher

For the sake of our patients and our profession, we need to improve upon the nineteenth-century pictograms that are currently used for visual assessment.

Business & Profession Retina

See the Benefits of a Good Workout

| Mark Hillen

Mice that take exercise exhibit slower retinal degeneration than those that don’t. It could work for people too.

Business & Profession Other

Benchmarking Ophthalmology

| Mark Hillen

Our cataloging of the major eye diseases is insightful, even though impact factor analysis is flawed.

Business & Profession Other

Questioning the “Critical Period”

| Mark Hillen

Received wisdom says that there is a critical period after birth during which the brain is wired for sight; blindness then means blindness for life

Business & Profession Professional Development

The Philanthropic Ophthalmologist

| Richard Gallagher

Be it battling blindness one patient at a time or changing global healthcare policies, ophthalmologists demonstrate admirable altruism.

Business & Profession Other

The Ophthalmologist Power List 2014

| Richard Gallagher

Ranking the 100 most influential people in ophthalmology. Which clinicians and researchers have the biggest impact on our field?

Business & Profession Basic & Translational Research

Gene Therapy Clinical Trials

| Irv Arons, Mark Hillen

The EMA approved the first gene therapy agent in 2012 – for lipoprotein lipase deficiency. Might gene therapies for ophthalmic disease reach the wards any time soon?

Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: